ZURA BIO LIMITED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
ZURA BIO LIMITED (ZURA) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $5.24 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-03-19
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-12-31 was $0.00.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-09-30 was $3.87M.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-06-30 was $768.00K, a 44.36% increase year-over-year.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-03-31 was $606.00K.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $5.24M.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$724.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.87M derived: sum of 2 quarters · filed 2026-03-19 | $4.63M derived: sum of 3 quarters · filed 2026-03-19 | $5.24M 10-K · filed 2026-03-19 |
| 2024-09-30 | $3.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.63M derived: sum of 2 quarters · filed 2024-11-07 | $5.24M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $768.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.37M 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | $606.00K 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | -$724.00K 10-K · filed 2025-03-25 | |||
| 2023-09-30 | -$119.00K 10-Q · filed 2023-11-13 | $413.00K derived: sum of 2 quarters · filed 2023-11-13 | $236.00K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2023-06-30 | $532.00K 10-Q · filed 2023-11-13 | $532.00K 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | -$177.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |